clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Faghih R et al. Synthesis and antibacterial activity of (9S)-9-dihydroclarithromycin. 1990 J. Antibiot. pmid:2147921
Perronne C et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. 1990 Antimicrob. Agents Chemother. pmid:2171421
Morimoto S et al. Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032. 1990 J. Antibiot. pmid:2139023
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Marchi E Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. 1990 Curr Med Res Opin pmid:2140546
Scaglione F Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. 1990 Curr Med Res Opin pmid:2140547
Morimoto S et al. Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. 1990 J. Antibiot. pmid:2141599
Hardy DJ et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. 1990 Antimicrob. Agents Chemother. pmid:2143642
Cacciapuoti AF et al. Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. 1990 J. Antibiot. pmid:2145254
Adachi T et al. Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A. 1989 J. Antibiot. pmid:2737946
Gorzynski EA et al. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. 1989 Antimicrob. Agents Chemother. pmid:2524998
Fernandes PB et al. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. 1989 Antimicrob. Agents Chemother. pmid:2523688
Fernandes PB et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. 1989 Antimicrob. Agents Chemother. pmid:2530933
Kohno Y et al. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. 1989 Antimicrob. Agents Chemother. pmid:2526615
Tinel M et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. 1989 J. Pharmacol. Exp. Ther. pmid:2527301
Adachi T et al. Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides. 1989 J. Antibiot. pmid:2529234
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Sasaki J et al. Microbial transformation of 6-O-methylerythromycin derivatives. 1988 J. Antibiot. pmid:2971032
Adachi T et al. 14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. 1988 J. Antibiot. pmid:2971033
Waites KB et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. 1988 Antimicrob. Agents Chemother. pmid:2973283
Barry AL et al. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. 1988 J. Clin. Microbiol. pmid:2976773
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Barry AL et al. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. 1988 Antimicrob. Agents Chemother. pmid:2840016
Segreti J et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2952061
Benson CA et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2952063
Barry AL et al. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. 1987 Antimicrob. Agents Chemother. pmid:2952064
Chin NX et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. 1987 Antimicrob. Agents Chemother. pmid:2953303
Bowie WR et al. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2953304
Hanson CW et al. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). 1987 J. Clin. Microbiol. pmid:2954995
Floyd-Reising S et al. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. 1987 Antimicrob. Agents Chemother. pmid:2955742
Fernandes PB et al. Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. 1987 Antimicrob. Agents Chemother. pmid:2957954
Fernandes PB et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. 1986 Antimicrob. Agents Chemother. pmid:2949695
Morimoto S et al. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. 1984 J. Antibiot. pmid:6706855
Pike VW et al. Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. 1984 Int J Appl Radiat Isot pmid:6231252
Granda Martín MJ et al. [Mycoplasma-associated acute hepatitis in an adult patient without pulmonary involvement]. Gastroenterol Hepatol pmid:24569138
Di Mario F et al. Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J. Clin. Gastroenterol. pmid:12702979
Alsohaibani F et al. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol pmid:26228365
Zullo A et al. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol pmid:22249086
Monego F et al. Molecular identification and typing of Mycobacterium massiliense isolated from postsurgical infections in Brazil. Braz J Infect Dis pmid:22230849
Kim MD et al. Ergotamine-induced upper extremity ischemia: a case report. Korean J Radiol pmid:15968153
Dharmalingam S et al. Relationship of plasmid profile with the antibiotic sensitivity pattern of Helicobacter pylori isolates from peptic ulcer disease patients in Chennai. Indian J Med Microbiol pmid:17643038
Can C et al. Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. Allergol Immunopathol (Madr) pmid:23253684
Agha Z et al. Is antibiotic prophylaxis for bacterial endocarditis cost-effective? Med Decis Making pmid:15951458
Kekilli M et al. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol pmid:27748322
Caliskan R et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev. Soc. Bras. Med. Trop. pmid:26108005
Siemens J et al. Transport of pharmaceuticals in columns of a wastewater-irrigated Mexican clay soil. J. Environ. Qual. pmid:20830907
Ubhayawardana NL et al. Detection of clarithromycin-resistant Helicobacter pylori strains in a dyspeptic patient population in Sri Lanka by polymerase chain reaction-restriction fragment length polymorphism. Indian J Med Microbiol pmid:26068338
Iwańczak BM et al. Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics. Adv Clin Exp Med pmid:27629844
Hajiaghamohammadi AA et al. To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori. Braz J Infect Dis pmid:27614124
Baylor P and Larson R Mycobacterium avium septicemia with ARDS in a patient with diabetes mellitus and no other known immune-compromising condition. J Intensive Care Med pmid:19188269
Set R and Shastri J Laboratory aspects of clinically significant rapidly growing mycobacteria. Indian J Med Microbiol pmid:22120792
Vlachogianni P et al. Mycobacterium avium Auricular Infection in an Apparent Immunocompetent Patient: A Case Report. Folia Med (Plovdiv) pmid:27552790
Kim HY et al. Allele-specific duplex polymerase chain reaction to differentiate Mycobacterium abscessus subspecies and to detect highly clarithromycin-resistant isolates. Indian J Med Microbiol pmid:27514964
Colomina Rodríguez J et al. [Impact of Integrated Model for Rational Use of Antibiotics in a health area (project MIURA)]. Rev. Esp. Salud Publica pmid:20661527
Yang X et al. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. Am J Ther pmid:25923229
Mégraud F [Helicobacter pylori infection: Review and practice]. Presse Med pmid:20627443
Vicente R et al. [Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study]. Gastroenterol Hepatol pmid:12139836
Yoon HJ et al. Nontuberculous mycobacterial tenosynovitis in the hand: two case reports with the MR imaging findings. Korean J Radiol pmid:22043158
Mégraud F Failed Eradication for Helicobacter pylori. What Should Be Done? Dig Dis pmid:27332826
Martins GM et al. MOLECULAR DETECTION OF CLARITHROMYCIN AND FLUOROQUINOLONES RESISTANCE IN HELICOBACTER PYLORI INFECTION, DIRECTLY APPLIED TO GASTRIC BIOPSIES, IN AN URBAN BRAZILIAN POPULATION. Arq Gastroenterol pmid:27305419
Wani FA et al. Antibiotic resistance in : A mutational analysis from a tertiary care hospital in Kashmir, India. Indian J Med Microbiol pmid:30084422
Rech TF et al. Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism. Braz J Infect Dis pmid:30048609
Wang B et al. In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates. Swiss Med Wkly pmid:30044468
Lage R et al. Mycobacterium chelonae cutaneous infection in a patient with mixed connective tissue disease. An Bras Dermatol pmid:25672306
Jeon JS et al. Detection of clarithromycin-resistant by polymerase chain reaction using residual samples from rapid urease test. Indian J Med Microbiol pmid:29063887
Hu JL et al. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol pmid:28937021
Melo-Cristino J et al. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000]. Acta Med Port pmid:11878155
Horiguchi T et al. Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection. J. Int. Med. Res. pmid:15458286
Zhang SH et al. The effect of virulence genotypes of on eradication therapy in children. Saudi J Gastroenterol pmid:29652033
Christodoulou C et al. Quetiapine and clarithromycin-induced neuroleptic malignant syndrome. Clin Neuropharmacol pmid:25580921
Feng L et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther pmid:25569598
Roig J et al. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents. Med Mal Infect pmid:17095177
Solé López J et al. [Consumption of antibiotics and their possible relationship with bacterial resistance in the "Costa de Ponent" health region: analysis of evolution through the initial and end periods of the last decade]. Aten Primaria pmid:15274900
Issa H et al. Bleeding duodenal ulcer after Roux-en-Y gastric bypass surgery: the value of laparoscopic gastroduodenoscopy. Ann Saudi Med pmid:20103961
Mishra A et al. A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin. Indian J Pharmacol pmid:25298587
Lew EA Clarithromycin, lansoprazole, and metronidazole eradicated Helicobacter pylori infection in chronic renal insufficiency. ACP J. Club pmid:15122860
Beck J Efficacy of esomeprazole in patients with acid-peptic disorders. Gastroenterol Nurs pmid:15082946
Asgari B et al. HONEY-DERIVED LACTOBACILLUS RHAMNOSUS ALLEVIATES HELICOBACTER PYLORI-INDUCED GASTRO-INTESTINAL INFECTION AND GASTRIC INFLAMMATION IN C57BL/6 MICE: AN IMMUNO-HISTOLOGIC STUDY. Arq Gastroenterol pmid:30540092
pmid:11817788
Torpiano P and Pace D Clinically-diagnosed Mediterranean Spotted Fever in Malta. Travel Med Infect Dis pmid:29462726
Bermejo Vicedo T et al. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia]. Farm Hosp pmid:15012176
Cohen ND et al. Use of Liposomal Gentamicin for Treatment of 5 Foals with Experimentally Induced Rhodococcus equi Pneumonia. J. Vet. Intern. Med. pmid:26692327
Liang CM et al. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J pmid:25163495
Wang J et al. Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. Saudi J Gastroenterol pmid:26655129
Chang NL et al. Clarithromycin-Induced Torsades de Pointes. Am J Ther pmid:25057773
Moreira C et al. Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. An Bras Dermatol pmid:28954125
Alkim H et al. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther pmid:26808355
Rush R and Sheth S Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration. Indian J Ophthalmol pmid:22446913
Seitz CS et al. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr) pmid:21269750
Dajani A et al. Importance of Helicobacter pylori eradcation for maintenance of remission of drug associated peptic ulcer disease. Saudi J Gastroenterol pmid:19858579
Doorakkers E et al. Helicobacter pylori eradication in the Swedish population. Scand. J. Gastroenterol. pmid:28323552
Moreira A et al. Is Helicobacter pylori infection associated with chronic idiopathic urticaria? Allergol Immunopathol (Madr) pmid:12890412
Cobos-Trigueros N et al. [Macrolides and ketolides]. Enferm. Infecc. Microbiol. Clin. pmid:19625112
Yamazhan T et al. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract pmid:16220015
Melo-Cristino J et al. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004. Rev Port Pneumol pmid:16572254
Pachot JI et al. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci pmid:12753725
Vaishnav P and Demain AL Unexpected applications of secondary metabolites. Biotechnol. Adv. pmid:21130862
Chen YI and Fallone CA A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting. Can J Gastroenterol Hepatol pmid:26301332
Lin TY et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J pmid:17939262
Radzikowska E et al. Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia. Adv Clin Exp Med pmid:28028949